Global healthcare companies, Genentech, Roche, and Biogen have initiated litigation proceedings against Dr. Reddy’s Laboratories (“DRL”) and Fresenius. The complaint, filed on November 17 in the U.S. District Court for the District of New Jersey, alleges infringement of 15 patents under the Biologics Price Competition and Innovation Act (BPCIA).
According to the plaintiffs, the controversy stems from Dr. Reddy’s Laboratories’ submission of an abbreviated Biologic License Application (aBLA) for DRL_RI, a proposed biosimilar of the widely used drug RITUXAN (rituximab), and concurrently serving a Notice of Commercial Marketing for the same. This move has reportedly led to the infringement of multiple patents held by Genentech, Roche, and Biogen.
RITUXAN is a widely administered medication known for its effective management of Non-Hodgkin’s lymphoma, Chronic Lymphocytic Leukemia and Rheumatoid Arthritis, among other conditions. If a lower-cost biosimilar is approved by the FDA and introduced to the market, it may lead to an industry reshuffling, with potential benefits for patients seeking more affordable treatment options.
Legally, the case presents multiple interesting issues for the BPCIA. The strategy of DRL to potentially bypass patents by applying for an aBLA and issuing a Notice of Commercial Marketing demonstrates the complex interplay between biosimilars and patent laws.
The full details of the complaint can be found in the original filing.
It is worth noting that this case presents a crucial development for lawmakers, regulatory authorities, and corporations, specifically concerning biosimilars and patent protections. How the court proceeds with this case could potentially impact future interpretations and enforcements of the BPCIA.